Zynerba Pharmaceuticals — Investor Presentation (September 2017)
30 slides from Zynerba Pharmaceuticals's investor presentation, Sep 11, 2017
Slide 1: Disclaimer
Disclaimer The statements in this presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things relate to the future operations,
Slide 2: Company Highlights
Company Highlights 3 Dedicated to developing and commercializing innovative transdermal pharmaceutically-produced cannabinoid therapeutics Experienced team with deep expertise and proven track record in CNS and pain drug development and commercialization, and patch and gel transdermal deliveries, su
Slide 3: Compelling Pipeline with Multiple Near-Term Milestones
Compelling Pipeline with Multiple Near-Term Milestones 4 ZYN002 patent protected through 2030 ZYN001 patent protected through 2031 Product Candidate Indication Preclinical Phase 1 Phase 2 Next Milestones ZYN001 – THC Pro-Drug Patch ZYN002 – CBD Gel Epilepsy in Adults with Focal Seizures Osteoarthrit
Slide 4: Zynerba Remains Well Positioned in the High-Growth Cannabinoid Space
Zynerba Remains Well Positioned in the High-Growth Cannabinoid Space 5 Zynerba’s transdermal approach has significant benefits Patent protection Scalable pharmaceutical manufacturing process Attractive COGS and no royalty obligations Sustained, controlled blood levels of drug with excellent tolerabi
Slide 5: Breadth of Therapeutic Opportunities
Breadth of Therapeutic Opportunities 6 Cannabinoids interact with specific receptors throughout the body to produce pharmacologic effects, mostly in the CNS and immune system. 9-tetrahydrocannabinol (9-THC) Cannabidiol (CBD) Possible indications Fibromyalgia Neuropathic Pain Appetite Nausea and vomi
Slide 6: ZYN002 CBD Gel Clinical Program
7 ZYN002 CBD Gel Clinical Program Developing pharmaceutically-produced CBD formulated as a patent-protected permeation-enhanced gel
Slide 7: ZYN002 – CBD Gel
ZYN002 – CBD Gel First and only patent-protected permeation-enhanced pharmaceutically-produced cannabidiol gel formulated for transdermal delivery The permeation enhancer in ZYN002 increases the delivery of CBD through the layers of the epidermis and into the circulatory system 8 CBD Delivery
Slide 8: ZYN002 CBD Gel Clinical Program: Fragile X Syndrome
9 ZYN002 CBD Gel Clinical Program Fragile X Syndrome
Slide 9: Fragile X Syndrome (FXS) Overview
Fragile X Syndrome (FXS) Overview 10 Autism spectrum disorder with no approved treatment options ~71,000 US patients1; most common inherited intellectual disability X-linked dominant; affects both males and females2 Intellectual disability, attention problems, anxiety, hyperactivity co-occur Autism,
Slide 10: Fragile X Syndrome Caused by FMR1 Mutation
Fragile X Syndrome Caused by FMR1 Mutation 11 Caused by a mutation in the Fragile X Mental Retardation gene located on the X chromosome Leads to dysregulation of the endocannabinoid pathway including the reduction in endogenous cannabinoids (2-AG and anandamide) Negatively affects synaptic function,
Slide 11: CBD May Effectively Treat Fragile X Syndrome
CBD May Effectively Treat Fragile X Syndrome Strong scientific rationale for CBD in FXS In mouse knock-out model, inhibition of the metabolism of 2-AG improves Fragile X syndrome symptoms CBD inhibits the metabolism of anandamide and 2-AG increasing availability of these cannabinoids CBD has strong
Slide 12: Fragile X Syndrome Phase 2 Clinical Trial Top Line Results Expected by End of September 2017
Fragile X Syndrome Phase 2 Clinical Trial Top Line Results Expected by End of September 2017 13 Maintenance Dosing initiated at CBD 50 mg Daily; may be titrated up to 250 mg* Daily Screening Titration Weeks 6 to 12 Day 1 to Week 6 Open label, doses of CBD 50 mg, 100 mg, or 250 mg* Daily *In 4.2% gel
Slide 13: FAB-C Exploratory Outcome Measures
FAB-C Exploratory Outcome Measures 14 Changes in Anxiety, Depression and Mood vs. Baseline as Measured by the ADAMS Scale Primary Outcome Measure Secondary Outcome Measures Clinical Global Impression – Improvement (CGI-I) Pediatric Anxiety Rating Scale (PARS-R) Aberrant Behavior Checklist – FXS Spec
Slide 14: ZYN002 CBD Gel Clinical Program: Osteoarthritis
15 ZYN002 CBD Gel Clinical Program Osteoarthritis
Slide 15: Potential Path Forward for ZYN002 in Osteoarthritis
Potential Path Forward for ZYN002 in Osteoarthritis 16 Phase 2 study data help clarify efficacy, safety, dose, inclusion and exclusion criteria, primary and secondary endpoints, & placebo response in OA patients FDA guidelines require pain & function endpoints in pivotal OA programs ZYN002 achieved
Slide 16: ZYN002 CBD Gel Clinical Program: Focal Epilepsy
17 ZYN002 CBD Gel Clinical Program Focal Epilepsy
Slide 17: STAR Study of ZYN002 in Focal Epilepsy
STAR 1 Study of ZYN002 in Focal Epilepsy 18 Primary and secondary endpoints did not reach statistical significance compared to placebo Excellent tolerability, consistent with previously released data Clinically meaningful reductions of seizures seen in ongoing STAR 2 open label extension Patients /
Slide 18: ZYN001 THC Pro-Drug Patch Clinical Program
19 ZYN001 THC Pro-Drug Patch Clinical Program Studying a pharmaceutically-produced pro-drug of THC in a state-of-the-art drug-adhesive matrix transdermal patch
Slide 19: ZYN001 – THC Pro-Drug Patch
ZYN001 – THC Pro-Drug Patch 20 Patent-protected pharmaceutically-produced D-glyceric acid ester-9-tetrahydrocannabinol in a transdermal patch ZYN001 is a pro-drug A drug administered in an inactive or less active form, designed to enable more effective delivery, and then converted into a different f
Slide 20: THC May Effectively Treat Fibromyalgia
THC is a CB1 agonist Has an analgesic effect in chronic pain models Acts at many sites along pain transmission pathways Nabilone (THC analogue) in patients with fibromyalgia Third-party 4-week, randomized, double-blind, placebo-controlled trial (N=40) — significant decreases in pain scores on multip
Slide 21: THC and Diabetic Peripheral Neuropathy Evidence
THC’s agonist effect on CB1 receptors modulates nociceptive thresholds by regulating neuronal activity Third-party randomized, double-blind, placebo-controlled crossover trial in diabetic peripheral neuropathy (DPN) demonstrated that THC is effective in reducing neuropathic pain 16 patients with DPN
Slide 22: ZYN001 Phase 1 Clinical Trial Underway
ZYN001 Phase 1 Clinical Trial Underway 24 24 hours 3.5 days 7 days Part 2: Multiple Dose Part 1: Single Dose 3:1 randomization, placebo controlled Multiple doses over 14 days Two formulations selected from Part 1 Multiple formulations of ZYN001 tested in each group 3:1 randomization, placebo control
Slide 23: ZYN001 – THC Pro-Drug Patch Phase 1 Clinical Program Underway
ZYN001 – THC Pro-Drug Patch Phase 1 Clinical Program Underway 25 Trial Patients Dosing PD Evaluations Phase 1 program: Part 1: Single Rising Doses in Normal Subjects Pharmacokinetic profile and tolerability evaluation of multiple formulations of ZYN001 Part 2: Multiple Rising Doses in Normal Subject
Slide 24: ZYN001 Preliminary Phase 2 Clinical Plan
26 Note: Subject to change due to further regulatory, clinical and other considerations. Trial Patients Dosing Primary Endpoint Timing Efficacy and Tolerability in Patients with Fibromyalgia Double-blind, placebo-controlled 120 patients 12 weeks Change from baseline in Fibromyalgia Impact Questionna
Slide 25: Strong Balance Sheet Provides Expected Runway into 2019
27 $70.2 million in cash & cash equivalents at 6/30/17 We believe that cash is sufficient to fund operations and capital requirements into 2019, including: Completing development of STAR 1 & 2, STOP and FAB-C Phase 2 trials for ZYN002 Completing Phase 1 and Phase 2 studies for ZYN001 Assuming suppor
Slide 26: Zynerba Remains Well Positioned in the High-Growth Cannabinoid Space
Zynerba Remains Well Positioned in the High-Growth Cannabinoid Space 28 Zynerba’s transdermal approach has significant benefits Patent protection Scalable pharmaceutical manufacturing process Attractive COGS and no royalty obligations Sustained, controlled blood levels of drug with excellent tolerab
Slide 27: Scientific Advisors
Jacqueline French, MD Professor of Neurology, NYU Langone Medical Center John Messenheimer, MD Consultant, Neurologist/Epileptologist, John Messenheimer PLLC Michael Rogawski, MD, PhD Professor of Neurology, UC Davis Center for Neuroscience Rodney Radtke, MD Professor of Neurology, Duke University M
Slide 28: Investor Relations Analyst Coverage
Investor Relations 30 NASDAQ: ZYNE Analyst Coverage* Jefferies: Biren Amin, PhD Piper Jaffray: Charles C. Duncan, PhD Oppenheimer: Derek Archila H.C. Wainwright: Corey Davis, PhD Roth: Michael Higgins Canaccord Genuity: Arlinda Lee, PhD Cantor Fitzgerald: Elemer Piros, PhD Maxim: Gabrielle Zhou * No
Slide 29: September 2017
September 2017 A clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of innovative transdermal pharmaceutically-produced cannabinoid treatments for patients with high unmet medical needs
Slide 30: company dedicated to the development and
company dedicated to the development and commercialization of innovative transdermal pharmaceutically-produced cannabinoid treatments for patients with high unmet ‘al needs September 2017
Zynerba Pharmaceuticals — Investor Presentation (September 2017) on 6ix